Valerie Diele-Braun nominated to succeed Piet van der Slikke as CEO of IMCD as of January 2024
ROTTERDAM, The Netherlands (15 March 2023) – IMCD N.V. (“IMCD” or “Company”), a leading distributor of speciality chemicals and ingredients, is pleased to announce that its Supervisory Board nominates Valerie Diele-Braun to become Chief Executive Officer of IMCD as of January 2024. Valerie will succeed Piet van der Slikke, who in December 2021 announced his intention to retire as CEO in 2024.
Valerie Diele-Braun is currently CEO of CABB Group GmbH, a leading global fine chemicals player and life science company, manufacturing active ingredients as well as advanced intermediates, and has over 20 years of leadership experience in the speciality chemicals and ingredients industry. She has been a member of IMCD’s Supervisory Board as of 30 June 2020.
Janus Smalbraak, chair of IMCD’s Supervisory Board: “Valerie brings a wealth of experience in our sector, leading with an international view and mindset. She has a track record of driving long-term business growth. While managing commercial as well as financial performance, Valerie has a keen eye for the sustainability requirements in the industry. Her nomination is the outcome of a thorough succession process. With Valerie we have found an excellent candidate to ensure the continuation of IMCD’s strong management, driving the business in the future ahead.”
Piet van der Slikke, CEO: “I’m delighted to welcome Valerie to our Management Board. Thanks to her role in the Supervisory Board, we have been able to work together in the last three years, in which she came across as an inspiring colleague with a catching mix of energy, experience and personality. I am looking forward to a smooth hand-over, supporting her to lead IMCD in its ambition for sustainable growth.”
Responsibilities
Valerie Diele-Braun has led the German headquartered CABB Group as CEO since 2018. CABB is a global contract development and manufacturing (CDMO) company, with sites throughout the world and a global client base. Prior she has been a member of the Executive Board of Swiss based chemicals manufacturer Achroma, responsible for two of the three global divisions of the company. She had senior executive positions with DSM Nutritional Products and Quest International (now part of Givaudan). Valerie holds a science degree from the State University of New York.
AGM
The appointment proposal will be put to the shareholders for their approval at the upcoming Annual General Meeting (AGM) to be held on 26 April 2023. Subject to shareholder approval, Valerie Diele-Braun will step down from the Supervisory Board and join the Management Board as of 1 October 2023. She will assume responsibilities as CEO and take over from Piet van der Slikke as of 1 January 2024.
To ensure a smooth leadership transition, Piet van der Slikke will remain available as advisor after the handover until 1 April 2024.
This press release contains information that qualifies as inside information within the meaning of Article 7(1) of the EU Market Abuse Regulation and was issued on 15 March 2023, 07:00 a.m. CET.
Attached, please find the full press release in pdf format.
Attachment
To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
GlobeNewswire by notifiedGlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
COMPLETION OF DIRECTED ISSUE OF 11,577,957 NEW B SHARES AND 250,000 EXISTING TREASURY B SHARES24.3.2023 00:50:07 CET | Press release
Ambu A/S (“Ambu” of the “Company”) has completed its offering of new B shares and existing treasury B shares (together the “Shares”) through an accelerated bookbuilding process (the “Offering”). Further to company announcement no. 6 of 24 March 2023, Ambu has successfully completed an accelerated bookbuild offering of 11,577,957 new B shares and 250,000 existing treasury B shares (in aggregate corresponding to approximately 5.3% of Ambu’s issued B shares), at a sales price of DKK 93 per share, raising gross proceeds to the Company of approximately DKK 1.1 billion. The board of directors of Ambu (the "Board") has today exercised its authorization in Article 9e(2) in Ambu’s Articles of Association, pursuant to which the Board is authorised to make share capital increases without pre-emption rights for the existing shareholders at a price not lower than market price, to increase Ambu's share capital by issue of 11,577,957 new B shares at a subscription price of DKK 93 per new B share. The
Årsrapport 202223.3.2023 22:58:17 CET | pressemeddelelse
Selskabsmeddelelse nr. 2 – 2023 København, den 23. marts 2023 Årsrapport 2022 Bestyrelsen i NTR Holding A/S har i dag behandlet og godkendt Selskabets årsrapport for regnskabsåret 2022. Årsrapporten har følgende hovedpunkter: NTR Holding koncernens salg af Daniamant A/S og Daniamant Ltd. blev gennemført den 31. januar 2022. Hovedparten af provenuet fra salget af Daniamant er udbetalt som udbytte. NTR Holding A/S har således i 2022 udbetalt udbytte på i alt DKK 49 pr. aktie, svarende til et samlet udbytte på DKK 121 mio. Bestyrelsen foreslår, at der ikke udloddes yderligere udbytte for 2022. Koncernens resultat af primær drift udviser et underskud på DKK 2,5 mio. (DKK -1,9 mio. i 2021), hvilket er i overensstemmelse med de senest udmeldte resultatforventninger. Koncernens totalindkomst udgør DKK 1,1 mio. Egenkapitalen udgør DKK 12,9 mio., svarende til en indre værdi pr. aktie på DKK 5,2. Bestyrelsen vil fortsat sondere NTR Holding A/S’ strategiske muligheder, herunder for at kapitaliser
Millicom (Tigo) announces a change in the Nomination Committee ahead of the 2023 Annual General Meeting23.3.2023 22:40:00 CET | Press release
Millicom (Tigo) announces a change in the Nomination Committee ahead of the 2023 Annual General Meeting Luxembourg, March 23, 2023 – The Nomination Committee of Millicom International Cellular S.A. (“Millicom”) announces that Mr. Nicolas Jaeger appointed by Atlas Luxco S.àr.l., has joined the Nomination Committee of Millicom. On March 17, 2023, Atlas Luxco S.àr.l. reported that it holds a 20% shareholding in Millicom. On March 23, 2023 Mr. Nicolas Jaeger joined the Nomination Committee. The Nomination Committee comprises Jan Dworsky, appointed by Swedbank Robur Funds; Viktor Kockberg, appointed by Nordea Investment Funds; Staley Cates, appointed by Southeastern Asset Management, Gerardo Zamorano appointed by Brandes Investment Partners, and Nicolas Jaeger appointed by Atlas Luxco S.àr.l., as well as the Chairman of Millicom’s Board of Directors, José Antonio Ríos García. Information about the work of the Nomination Committee can be found on Millicom’s website. Shareholders wishing to p
GreenMobility issues warrants23.3.2023 22:40:00 CET | Press release
Company Announcement no. 121– 2023 Copenhagen, March23rd, 2023 GreenMobility issues warrants The Board of Directors of GreenMobility A/S S (“GreenMobility” or the “Company”), has today resolved to grant warrants in the Company for the purpose of: Ensuring that shareholders, the Executive Management and other management employees of the Company have the same interests, and that everyone makes a special effort for the value creation in the Company and its subsidiaries.Retaining the Executive Management and management employees of the Company.Granting warrants to the Board of Directors as authorized at the 2021 Annual General Meeting but not yet granted Warrants granted will generally be subject to the existing warrant programs as publicized in company announcement no. 41 on November 19th, 2019 and in company announcement no. 64 on September 29th 2020 with certain deviations. The total issuance of warrants is in accordance with the resolutions passed at the Annual General Meetings held on
Inventiva announces the schedule of publication and presentation of its 2022 Full-Year Financial Results23.3.2023 22:00:00 CET | Press release
Daix (France), Long Island City (New York, United States), March 23, 2023 – Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of patients with non-alcoholic steatohepatitis (NASH) and other diseases with significant unmet medical needs, today announced that its management team will host a webcast to present the Company’s 2022 full-year financial results on Thursday, March 30, 2023. Inventiva’s 2022 full-year financial results will be published on Wednesday, March 29, 2023 at 4:00 pm (New York), 10:00 pm (Paris). Frédéric Cren, Chairman, CEO and cofounder of Inventiva, Pierre Broqua, Chief Scientific Officer and cofounder of Inventiva, Jean Volatier, Chief Financial Officer of Inventiva, and Michael Cooreman, Chief Medical Officer of Inventiva, will hold a conference call in English, followed by a Q&A session, onThursday, March 30, 2023, at8:00 am (New York)